Page 143 - Screening for Cervical Cancer: Systematic Evidence Review

Appendix C. Evidence Tables

Evidence Table 3A. Performance of HPV Testing for Screening (cont'd)

Quality
Patients & Methods Outcomes Measured Study Results & Limitations* Considerations
8554 women cytology: Bethesda Prevalence: Quality Score=9
randomly selected in a system Negative=7564/8554=88.4% Ref. Std: 2
door-to door survey Equivocal=661/8554=7.7% Blind: 0
HPV: : high risk types LG lesion=189/8554=2.2% Verification: 2
(16, 18, 31, 33, 35, HG lesion=128/8554=1.5% Consecutive: 2
45, 51, 52, 56 and 58) Cancer=12/8554=0.14% Spectrum: 1
vs. not Publication: 1
Se (High risk HPV by HCT, HG+)= Industry: 1
histology :negative, 74.1%
equivocal, low-grade Sp (High risk HPV by HCT, HG+)=
lesion, high-grade 93.4%
lesion, cancer
Se (High risk HPV by HC II, HG+)=
88.4%
Sp (High risk HPV by HC II, HG+)=
89.0%

(more screening performance
results available for different
cutpoints of HPV positivity)

466 women aged 25 HPV: high risk Prevalence: Quality Score=9
to 55 attending subtypes (16, 18, 31, Negative=350/466=75.1% Ref. Std: 2
primary care clinics 33, 35, 45, 51, 52, 56 LGSIL=60/466=12.9% Blind: 2
and 58) vs. not HGSIL=56/466=12% Verification: 2
Consecutive: 0
Biopsy/colposcopy: for HIV+ women: Spectrum: 1
Normal, low-grade Se (High risk HPV, LGSIL+)= 85.9% Publication: 1
lesion, high-grade Sp (High risk HPV, LGSIL+)= 47.0% Industry: 1
lesion, cancer
Se (High risk HPV, HGSIL)= 90.7%
Sp (High risk HPV, HGSIL )= 41.3%

for HIV- women:
Se (High risk HPV, LGSIL+)=45.2%
Sp (High risk HPV, LGSIL+)=75.3%

Se (High risk HPV, HGSIL)= 61.5%
Sp (High risk HPV, HGSIL )= 74.5%

C-49